Welcome to our dedicated page for iRhythm Holdings news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Holdings stock.
iRhythm Holdings, Inc. reports developments for a digital health care business focused on ambulatory cardiac monitoring and arrhythmia detection. The company’s recurring updates center on the Zio ambulatory ECG portfolio, which combines patch-based monitoring, AI-powered analysis, and clinical data review to deliver cardiac rhythm insights to physicians.
Company news commonly covers quarterly and annual financial results, revenue guidance, margin trends, and operating leverage, along with clinical evidence presented at cardiology meetings. Other updates include clinician education initiatives, investor conference participation, board and governance changes, and the company’s completed transition to a holding-company structure as successor registrant to iRhythm Technologies.
iRhythm (Nasdaq: IRTC) agreed for its subsidiary to acquire privately held VitalConnect for approximately $287.5 million, comprising about $237.5 million in cash funded from existing cash and roughly $50 million in iRhythm common stock. VitalConnect brings an FDA‑cleared wearable biosensor platform spanning multiple cardiac monitoring modalities, including mobile cardiac telemetry (MCT), and multi‑vitals monitoring for hospital and remote care.
According to iRhythm, the combination will broaden its ambulatory and inpatient cardiac monitoring portfolio, expand its addressable market and is expected to be accretive to iRhythm’s revenue growth rate beginning in 2027, while preserving its previously communicated 15% adjusted EBITDA margin target for 2027. iRhythm will also provide VitalConnect up to $30 million in interim working capital financing. Closing is targeted by the end of 2026, subject to regulatory and customary conditions.
iRhythm Holdings (NASDAQ: IRTC) reported second quarter 2026 revenue of $224.2 million, up 20.1% year over year, with gross margin of 72.8%, a 160-basis-point increase. GAAP net loss narrowed to $0.4 million, while adjusted net income reached $19.3 million and adjusted EBITDA was $43.3 million, representing a 19.3% adjusted EBITDA margin.
Unrestricted cash, cash equivalents and marketable securities totaled $591.3 million at June 30, 2026. iRhythm entered a definitive agreement to acquire VitalConnect for approximately $287.5 million, received FDA clearance for its third-generation algorithm, and raised full-year 2026 guidance to $880–$890 million in revenue and 13.0%–14.0% adjusted EBITDA margin.
Summary not available.
iRhythm Holdings (NASDAQ: IRTC) will report its second quarter 2026 financial results after the market close on Thursday, August 6, 2026. The company’s management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, with live and archived webcasts available in the “Quarterly Results” section of its investor website at investors.irhythmtech.com.
iRhythm Holdings (NASDAQ:IRTC) will participate in two upcoming investor conferences in June 2026.
The company is scheduled for the William Blair 46th Annual Growth Stock Conference on June 2, 2026, and the Truist Securities MedTech Conference on June 16, 2026. Live and archived webcasts will be available on its investor website.
iRhythm (NASDAQ: IRTC) reported Q1 2026 results: revenue $199.4M (+25.7% YoY), gross margin 70.9% (+210 bps), and adjusted EBITDA $14.1M (7.1% margin). Unrestricted cash and marketable securities totaled $549.6M at March 31, 2026.
The company raised 2026 guidance to $875M–$885M revenue and adjusted EBITDA margin 12%–13%, citing volume-led growth, gross margin expansion, and continued investments in AI-enabled cardiac solutions.
iRhythm Holdings (NASDAQ:IRTC) will present at the Bank of America Securities 2026 Health Care Conference on Wednesday, May 13, 2026 at 9:20 a.m. PT / 12:20 p.m. ET. The management presentation will be available via live webcast and archived replay on the company’s investor website.
Investors can access the presentation in the Events & Presentations section at investors.irhythmtech.com.
iRhythm (NASDAQ:IRTC) reported real-world analyses presented at HRS 2026 showing short-duration 24–48-hour Holter monitoring misses a substantial portion of arrhythmias compared with up to 14 days of continuous Zio ambulatory ECG monitoring.
Key findings: post-ablation AF recurrence was 21% overall with 26% of first recurrences detected after 48 hours, and pregnancy monitoring found arrhythmias in 37.7% of patients with 13.6% clinically significant—most detected after 48 hours.
iRhythm Holdings (NASDAQ:IRTC) will report first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET with a live and archived webcast available.
Investors may access the webcast via the Quarterly Results section of the company investor website at investors.irhythmtech.com.
iRhythm (NASDAQ: IRTC) reported retrospective ACC.26 analyses showing a high prevalence of clinically actionable arrhythmias across cardiometabolic and kidney-metabolic (CKM) populations and launched iRhythm Academy clinician education. Key findings: 48% arrhythmia prevalence in CKD, 47% with both diabetes+CKD, AF prevalence rose from 4.5% to 6.5% with severe obesity, adjusted AF odds ratio 2.8.
Company highlighted AI scaling in cardiology and announced a Spanish-language update to the MyZio mobile app.